

Activation of GLP-1 Receptors Suppresses Pathological Defensive Aggression via DMPAG in Mice

Yiran Liu^{1,2,3,#}, Xiao Liu^{1,2,3,#}, Xueyong Yin^{1,2,3,#}, Yunluo Li^{1,2}, Xiaohui Yu¹, Xinyu Nan¹, Jiping Xue^{1,2}, Hengtai Lu^{1,2}, Bingyu Li^{1,2}, Fei Zhou^{1,2}, Xiaoyu Liu^{1,2}, Xiangyu Zhang^{1,2}, Xiangjun He^{1,2}, Xi Yu^{1,2}, Shu Yan^{1,2}, Yating Li^{1,2,4}, Shuang Wang¹, Yuan Gao^{1,3}, Yifan Liu^{1,2}, Ying Kang^{1,2}, Jingwen Zhang^{1,2}, Ye Zhao^{1,2,3,*}, Haishui Shi^{1,2,3,4,*}

Figure S1. Temporal effects of a single central liraglutide administration on defensive aggression in male and female mice. (A) Experimental timeline. Group-housed male and female mice were implanted with ICV cannulas and allowed to recover for 7 days. Liraglutide or saline was administered 20 min before DAT on day 14, and DAT was subsequently assessed once daily from day 15 to day 18. **(B)** Quantification of latency of biting, number of biting, and time for biting in male mice. **(C)** Quantification of latency of biting, number of biting, and time for biting in female mice. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$. GLP-1RA, glucagon-like peptide-1 receptor agonist; ICV, intracerebroventricular; DAT, defensive attack test.

Figure S2. Acute peripheral liraglutide administration does not alter OFT or DAT performance in male and female mice. (A) Experimental timeline. Group-housed male and female mice received I.P. administration of liraglutide or saline 20 min before testing. The OFT was performed 1 day before the DAT. **(B, D)** Representative traces and quantification of total distance traveled and time spent in the center in the OFT in male (B)

and female (D) mice. **(C, E)** Quantification of latency of biting, number of biting, and time for biting in the DAT in male (C) and female (E) mice. GLP-1RA, glucagon-like peptide-1 receptor agonist; I.P., intraperitoneal; OFT, open field test; DAT, defensive attack test.

Figure S3. Local co-administration of carnosine and MK-801 in the DMPAG does not clearly reverse the suppressive effect of carnosine on defensive aggression. (A) Experimental timeline. Group-housed male mice were implanted with cannulas and allowed to recover for 7 days. Carnosine, MK-801, or carnosine + MK-801 was administered into the DMPAG 10 min before DAT. **(B)** Quantification of latency of biting, number of biting, and time for biting in the DAT. * $p < 0.05$; ** $p < 0.01$. DAT, defensive attack test; DMPAG, dorsomedial periaqueductal gray.

Figure S4. Representative immunofluorescence image showing GLP-1R immunoreactivity and c-Fos-positive cells in the DMPAG. (A) Representative image of GLP-1R immunoreactivity (green), c-Fos-positive cells (red), and DAPI (blue) staining in the DMPAG, with an enlarged view of the highlighted region. DMPAG, dorsomedial periaqueductal gray; GLP-1R, glucagon-like peptide-1 receptor.

Figure.S1








Figure.S2


A




B



C



D



E





Figure.S3

A



B




Figure.S4

A

DMPAG

